Cargando…

Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors

[Image: see text] N(1)-Hydroxy-N(8)-ferrocenyloctanediamide, JAHA (7), an organometallic analogue of SAHA containing a ferrocenyl group as a phenyl bioisostere, displays nanomolar inhibition of class I HDACs, excellent selectivity over class IIa HDACs, and anticancer action in intact cells (IC(50) =...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spencer, John, Amin, Jahangir, Wang, Minghua, Packham, Graham, Alwi, Sharifah S. Syed, Tizzard, Graham J., Coles, Simon J., Paranal, Ronald M., Bradner, James E., Heightman, Tom D.
Formato:	Texto
Lenguaje:	English
Publicado:	American Chemical Society 2011
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093745/ https://www.ncbi.nlm.nih.gov/pubmed/21572592 http://dx.doi.org/10.1021/ml100295v

Ejemplares similares

Probing the Anticancer Action of Novel Ferrocene Analogues of MNK Inhibitors
por: Sansook, Supojjanee, et al.
Publicado: (2018)

The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells
por: Librizzi, Mariangela, et al.
Publicado: (2015)

One Year of JAHA
por: Vita, Joseph A.
Publicado: (2013)

JAHA : The End of the Beginning
por: London, Barry
Publicado: (2022)

JAHA Spotlight on Psychosocial Factors and Cardiovascular Disease
por: Peterson, Pamela N.
Publicado: (2020)

JAHA Go Red for Women Spotlight 2023
por: Mujahid, Mahasin S., et al.
Publicado: (2023)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

JAHA: The American Heart Association's Open Access Journal
por: Vita, Joseph A
Publicado: (2012)

JAHA Spotlight on Racial and Ethnic Disparities in Cardiovascular Disease
por: Mazimba, Sula, et al.
Publicado: (2021)

Diversity, Equity, and Inclusiveness in Medicine and Cardiology: Next Steps for JAHA
por: London, Barry, et al.
Publicado: (2020)

JAHA Spotlight on Pregnancy and Its Impact on Maternal and Offspring Cardiovascular Health
por: Russell, Mark W.
Publicado: (2022)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

JAHA Spotlight on Air Pollution and Cardiovascular Disease: A Call for Urgent Action
por: Gupta, Ajay K.
Publicado: (2021)

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017)

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells
por: Lineham, Ella, et al.
Publicado: (2018)

Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors
por: Gupta, Ajay K., et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Synthesis and solid-state characterisation of 4-substituted methylidene oxindoles
por: Tizzard, Graham J, et al.
Publicado: (2013)

N 1-Arylation of 1,4-Benzodiazepine-2-ones with Diaryliodonium Salts
por: Khan, Raysa, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Histone deacetylase 3 indirectly modulates tubulin acetylation
por: Bacon, Travis, et al.
Publicado: (2015)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Histone Deacetylase Inhibition and Dietary Short-Chain Fatty Acids
por: Licciardi, Paul V., et al.
Publicado: (2011)

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
por: Kalin, Jay H., et al.
Publicado: (2018)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ev2hh5djipecp0jnos07lfov76